Globavir Announces Licensing Agreement with Bio-Rad for Globavir’s Dengue Detection Technology
Original Article Featured on Globavir
LOS ALTOS, Calif., Oct. 17, 2016 /PRNewswire/ — Globavir Biosciences, Inc., a biotechnology company that develops therapeutics for infectious diseases and oncology, and diagnostics for infectious diseases, announced a partnership with Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostics products. Under the terms of the agreement, Bio-Rad will license Globavir’s PanGlobTM dengue detection technology for use in an assay that includes dengue virus detection. Financial terms of the agreement were not disclosed.
The PanGlob assay, originally developed by Stanford University researchers, includes improved diagnostic sensitivity, efficacy across all four dengue serotypes, and enhanced specificity for dengue over related viruses. This advanced technology reduces the risk of incorrect results.